Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus.
Rupesh RainaRolla Abu-ArjaSidharth SethiRicha DuaRonith ChakrabortyJames T DibbRajit K BasuJohn BisslerMelvin Bonilla FelixPatrick BrophyTimothy BunchmanKhalid AlhasanDieter HaffnerYap Hui KimChristopher LichtMignon McCullochShina MenonAli Mirza OnderPrajit KhooblallAmrit KhooblallVeronika PolishchukHemalatha RangarajanAzmeri SultanaClifford KashtanPublished in: Pediatric nephrology (Berlin, Germany) (2022)
Hematopoietic cell transplantation (HCT) is a common therapy for the treatment of neoplastic and metabolic disorders, hematological diseases, and fatal immunological deficiencies. HCT can be subcategorized as autologous or allogeneic, with each modality being associated with their own benefits, risks, and post-transplant complications. One of the most common complications includes acute kidney injury (AKI). However, diagnosing HCT patients with AKI early on remains quite difficult. Therefore, this evidence-based guideline, compiled by the Pediatric Continuous Renal Replacement Therapy (PCRRT) working group, presents the various factors that contribute to AKI and recommendations regarding optimization of therapy with minimal complications in HCT patients.
Keyphrases
- acute kidney injury
- cardiac surgery
- cell cycle arrest
- end stage renal disease
- risk factors
- bone marrow
- chronic kidney disease
- ejection fraction
- newly diagnosed
- clinical practice
- cell death
- stem cell transplantation
- prognostic factors
- peritoneal dialysis
- stem cells
- cell proliferation
- mesenchymal stem cells
- replacement therapy